Table 3.
Positive associations between bowel dosimetry/toxicity
| Clinician-reported toxicity | |||||
|---|---|---|---|---|---|
| Cohort | Threshold | LENT-SOMA | % patients with toxicity | RTOG | % patients with toxicity |
| CFRT | M | N/A | N/A | ||
| MS | bV45 and consistency/frequency management (P = 0.01, δM = 52.7) | 6% | bV45 and bowel frequency (P = 0.04, δM = 16.96) | 10% | |
| bV55 and bowel frequency (P = 0.03, δM = 3.8) | 10% | ||||
| HFRT-4D | M | bV39 and frequency (P = 0.03, δM = 17.66) | 30% | bV39 and diarrhoea (P = 0.03, δM = 17.32) | 25% |
| bV43 and diarrhoea (P = 0.01, δM = 7.39) | 25% | ||||
| bV47 and diarrhoea (P = 0.002, δM = 2.15) | 25% | ||||
| MS | bV39 and frequency (P = 0.02, δM = 27.5) | 13% | bV39 and bowel frequency (P = 0.04, δM = 27.17) | 11% | |
| bV43 and consistency (P = 0.04, δM = 8.33) | 10% | bV43 and diarrhoea (P = 0.03, δM = 24.50) | 9% | ||
| HFRT-5D | M | bV39 and consistency (P = 0.05, δM = 32.59) | 26% | N/A | |
| bV43 and consistency (P = 0.03, δM = 15.99) | 26% | ||||
| bV43 and frequency (P = 0.05, δM = 13.48) | 31% | ||||
| MS | bV43 and consistency (P = 0.04, δM = 18.76) | 17% | N/A | ||
| Patient-reported toxicity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Urgency |
Loose stools |
Distress |
Crampy pain |
Problem |
||||||
| Threshold → |
M | MS | M | MS | M | MS | M | MS | M | MS |
| Cohort ↓ | ||||||||||
| CFRT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| % patients with toxicity | – | – | – | – | – | – | – | – | – | – |
| HFRT-4D | bV43 (P = 0.006, δM = 7.04) |
bV43 (P = 0.009, δM = 8.8) bV47 (P = 0.03, δM = 1.55) |
bV39 (P = 0.009, δM = 24.78) bV43 (P = 0.0005, δM = 11.74) bV47 (P = 0.05, δM = 0.07) |
N/A | bV43 (P = 0.04, δM = 4.10) | N/A | N/A | N/A | bV39 (P = 0.04, δM = 10.50) bV43 (P = 0.002, δM = 11.37) |
bV39 (P = 0.04, δM = 14.20) bV43 (P = 0.003, δM = 12.22) bV47 (P = 0.03, δM = 2.01) |
| % patients with toxicity | 41% | 33% | 43% | – | 34% | – | – | – | 54% | 39% |
| HFRT-5D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| % patients with toxicity | – | – | – | – | – | – | – | – | – | – |
Where N/A is reported, no positive associations were found. Where P ≤ 0.01, results are in bold. Where results were significant after Holm correction, results are bold and italicized. M = mild threshold (symptomatic patients are defined as having mild or worse symptoms). MS = moderate/severe (symptomatic patients are defined as having moderate or worse symptoms). % of patients with toxicity events excludes patients where data was unavailable (for full results see supplementary Tables R1–R9).